Does the media prefer VRCA or AIXC?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Qualigen Therapeutics' average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.63 indicating that Qualigen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AIXC or PEPG?

PepGen has a consensus target price of $11.60, suggesting a potential upside of 683.78%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PepGen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better earnings & valuation, AIXC or PEPG?

PepGen is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is AIXC or PEPG more profitable?

PepGen's return on equity of -59.89% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% PepGen N/A -59.89% -49.62%

Does the media refer more to AIXC or PEPG?

In the previous week, PepGen had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat PepGen's score of 0.51 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CRDF or AIXC?

Cardiff Oncology presently has a consensus price target of $8.75, indicating a potential upside of 464.52%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Cardiff Oncology is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CRDF or AIXC?

In the previous week, Cardiff Oncology had 5 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat Cardiff Oncology's score of 0.06 indicating that Qualigen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BMEA or AIXC?

Biomea Fusion presently has a consensus target price of $8.50, suggesting a potential upside of 522.71%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BMEA or AIXC?

Biomea Fusion is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is BMEA or AIXC more profitable?

Biomea Fusion's return on equity of -265.37% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Qualigen Therapeutics N/A -771.52% -79.52%

Does the media prefer BMEA or AIXC?

In the previous week, Biomea Fusion had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat Biomea Fusion's score of 0.62 indicating that Qualigen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIXC or FTLF?

FitLife Brands has a consensus price target of $21.50, indicating a potential upside of 116.30%. Given FitLife Brands' stronger consensus rating and higher probable upside, analysts clearly believe FitLife Brands is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to AIXC or FTLF?

In the previous week, FitLife Brands had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for FitLife Brands and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat FitLife Brands' score of 0.39 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FitLife Brands 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Qualigen Therapeutics (AIXC) Competitors

$1.29 +0.03 (+2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.28 -0.01 (-0.39%)

As of 04:10 PM Eastern

Compare

AIXC vs. VRCA, PEPG, CRDF, BMEA, and FTLF

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include Verrica Pharmaceuticals (VRCA), PepGen (PEPG), Cardiff Oncology (CRDF), Biomea Fusion (BMEA), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Verrica Pharmaceuticals presently has a consensus price target of $14.50, indicating a potential upside of 135.77%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Verrica Pharmaceuticals is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Qualigen Therapeutics' average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.63 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qualigen Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Qualigen Therapeutics' return on equity of -771.52% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Qualigen Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.97	-$17.89M	-$1.03	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

Summary

Verrica Pharmaceuticals beats Qualigen Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Qualigen Therapeutics compare to PepGen?

Qualigen Therapeutics (NASDAQ:AIXC) and PepGen (NASDAQ:PEPG) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Qualigen Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, PepGen has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

In the previous week, PepGen had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat PepGen's score of 0.51 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

PepGen has a consensus target price of $11.60, suggesting a potential upside of 683.78%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

PepGen's return on equity of -59.89% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
PepGen	N/A	-59.89%	-49.62%

PepGen is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

PepGen beats Qualigen Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Cardiff Oncology presently has a consensus price target of $8.75, indicating a potential upside of 464.52%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Cardiff Oncology is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cardiff Oncology has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cardiff Oncology had 5 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat Cardiff Oncology's score of 0.06 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qualigen Therapeutics has lower revenue, but higher earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	179.62	-$45.85M	-$0.67	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

Qualigen Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Summary

Cardiff Oncology beats Qualigen Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biomea Fusion is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

Biomea Fusion presently has a consensus target price of $8.50, suggesting a potential upside of 522.71%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biomea Fusion's return on equity of -265.37% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Biomea Fusion has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

In the previous week, Biomea Fusion had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat Biomea Fusion's score of 0.62 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biomea Fusion beats Qualigen Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to FitLife Brands?

Qualigen Therapeutics (NASDAQ:AIXC) and FitLife Brands (NASDAQ:FTLF) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Qualigen Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

FitLife Brands has a consensus price target of $21.50, indicating a potential upside of 116.30%. Given FitLife Brands' stronger consensus rating and higher probable upside, analysts clearly believe FitLife Brands is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, FitLife Brands had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for FitLife Brands and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat FitLife Brands' score of 0.39 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FitLife Brands	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

FitLife Brands has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
FitLife Brands	$81.46M	1.15	$6.33M	$0.60	16.57

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 61.4% of FitLife Brands shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

FitLife Brands has a net margin of 6.64% compared to Qualigen Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
FitLife Brands	6.64%	18.31%	8.21%

Summary

FitLife Brands beats Qualigen Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIXC vs. The Competition

Export

Metric	Qualigen Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$26.11M	$993.40M	$4.35B	$12.46B
Dividend Yield	N/A	4.84%	7.42%	5.22%
P/E Ratio	-0.20	1.49	21.82	24.36
Price / Sales	N/A	125.49	176.08	117.07
Price / Cash	N/A	20.06	58.60	57.13
Price / Book	-1.72	8.12	30.95	6.73
Net Income	-$16.97M	-$3.91M	$109.80M	$337.03M
7 Day Performance	4.88%	-1.72%	-0.42%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	N/A	111.96%	15.64%	33.98%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIXC Qualigen Therapeutics	0.5126 of 5 stars	$1.29 +2.4%	N/A	N/A	$26.11M	N/A	N/A	50
VRCA Verrica Pharmaceuticals	2.8282 of 5 stars	$5.86 +1.2%	$14.50 +147.4%	+10.5%	$101.19M	$35.58M	N/A	40
PEPG PepGen	3.0193 of 5 stars	$1.42 -1.8%	$11.60 +714.6%	-7.2%	$98.57M	N/A	N/A	30	Analyst Downgrade
CRDF Cardiff Oncology	2.2089 of 5 stars	$1.41 -7.0%	$8.75 +522.8%	-60.1%	$96.06M	$590K	N/A	20	News Coverage Analyst Downgrade High Trading Volume
BMEA Biomea Fusion	2.0394 of 5 stars	$1.30 -5.4%	$8.50 +555.9%	-47.8%	$94.35M	N/A	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIXC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. VRCA, PEPG, CRDF, BMEA, and FTLF

How does Qualigen Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Qualigen Therapeutics compare to PepGen?

Summary

How does Qualigen Therapeutics compare to Cardiff Oncology?

Summary

How does Qualigen Therapeutics compare to Biomea Fusion?

Summary

How does Qualigen Therapeutics compare to FitLife Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. VRCA, PEPG, CRDF, BMEA, and FTLF

How does Qualigen Therapeutics compare to Verrica Pharmaceuticals?

Do insiders and institutionals believe in VRCA or AIXC?

Which has more risk and volatility, VRCA or AIXC?

Do analysts prefer VRCA or AIXC?

Does the media prefer VRCA or AIXC?

Is VRCA or AIXC more profitable?

Which has higher valuation and earnings, VRCA or AIXC?

Summary

How does Qualigen Therapeutics compare to PepGen?

Which has more risk & volatility, AIXC or PEPG?

Does the media refer more to AIXC or PEPG?

Do analysts prefer AIXC or PEPG?

Is AIXC or PEPG more profitable?

Which has better earnings & valuation, AIXC or PEPG?

Do insiders & institutionals believe in AIXC or PEPG?

Summary

How does Qualigen Therapeutics compare to Cardiff Oncology?

Do analysts recommend CRDF or AIXC?

Which has more volatility and risk, CRDF or AIXC?

Do institutionals and insiders believe in CRDF or AIXC?

Does the media prefer CRDF or AIXC?

Which has preferable valuation and earnings, CRDF or AIXC?

Is CRDF or AIXC more profitable?

Summary

How does Qualigen Therapeutics compare to Biomea Fusion?

Do insiders and institutionals hold more shares of BMEA or AIXC?

Which has stronger earnings and valuation, BMEA or AIXC?

Do analysts recommend BMEA or AIXC?

Is BMEA or AIXC more profitable?

Which has more risk & volatility, BMEA or AIXC?

Does the media prefer BMEA or AIXC?

Summary

How does Qualigen Therapeutics compare to FitLife Brands?

Which has more risk and volatility, AIXC or FTLF?

Do analysts recommend AIXC or FTLF?

Does the media refer more to AIXC or FTLF?

Which has preferable earnings and valuation, AIXC or FTLF?

Do insiders & institutionals have more ownership in AIXC or FTLF?

Is AIXC or FTLF more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools